Onxeo

Business and Financial Review • Jan 7, 2016

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH CM-CIC Securities

As part of the liquidity contract entrusted by ONXEO to CM-CIC, the following assets appeared on the liquidity account as of December 31, 2015:

• 31,866 shares
• 105,135.27 € in cash

As a reminder, as of June 30, 2015, the following assets appeared on the liquidity account:

• 14,000 shares
• 195,808.71 € in cash

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad® ): Phase II in severe oral mucositis: Positive final results Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral T-cell lymphoma For more information, visit the website www.onxeo.com

Contacts : Nathalie Delair-Trepo Investor Relations, Onxeo investors@onxeo.com +33 1 45 58 76 00

Caroline Carmagnol / Florence Portejoie – Alize RP (France) onxeo@alizerp.com +33 6 64 18 99 59 / +33 1 44 54 36 64